RETA — Retatrutide
Retatrutide is a triple hormone receptor agonist currently in clinical investigation, studied in metabolic research models.
Agonizes GLP-1R (central satiety, insulin secretion), GIPR (incretin effect, adipocyte lipolysis), and glucagon receptor (thermogenesis, hepatic glucose suppression, fat mobilisation). Triple agonism addresses the complete metabolic circuit simultaneously.
Key Benefits
- Body weight reduction
- Triple receptor synergy
- Enhanced thermogenesis
- Improved insulin sensitivity
- Liver fat reduction (NASH)
⚠️ Not approved by FDA for any use, in active clinical trials. FOR RESEARCH ONLY!
Disclaimer
For research purposes only. Not for human or animal use and not FDA-approved. By purchasing, you confirm that you are 21 years of age or older and are a qualified researcher.
Safety and Compliance Statement
This material is intended solely for research purposes under the guidance of qualified professionals. GHK-CU is not approved for human or animal consumption and should be handled with appropriate caution, following established laboratory protocols. Users are advised to conduct experiments in compliance with institutional regulations and safety standards.
For research use only. Not for human or animal consumption.
